MS Pharma Equity (EBRD-47793)

Regions
  • Middle East and North Africa
Where the impacts of the investment may be experienced.
Financial Institutions
  • European Bank for Reconstruction and Development (EBRD)
International, regional and national development finance institutions. Many of these banks have a public interest mission, such as poverty reduction.
Project Status
Active
Bank Risk Rating
B
Risk rating varies among banks and may refer only to the particular investment and not to the risk for the project as a whole. Projects marked 'U' have an 'Unknown' risk rating at the time of disclosure.
Voting Date
May 25, 2016
The estimate day the bank will vote on a proposed investment. The decision dates may change, so review updated project documents or contact the EWS team.
Borrower
MS Pharma Partners Holding W.L.L.
The holder of the loan, grant, or other investment.
Sectors
  • Industry and Trade
The service or industry focus of the investment. A project can have several sectors.
Investment Amount (USD)
$ 50.00 million
Value listed on project documents at time of disclosure. If necessary, converted to USD$. Please review updated project documents for more information.
Project Cost (USD)
$ 50.00 million
Value listed on project documents at time of disclosure. If necessary, converted to USD$. Please see updated project documentation for more information.
Bank Documents
Primary Source

Original disclosure @ EBRD website

Updated in EWS Jan 2, 2018

Disclosed by Bank Sep 9, 2016


Contribute Information
Can you contribute information about this project?
Contact the EWS Team

Project Description
PROJECT DESCRIPTION A USD 50 million equity investment in MS Pharma Partners Holding W.L.L., a subsidiary of MS Pharma Ventures Holdings W.L.L., a manufacturer of generic pharmaceuticals operating in the MENA region. PROJECT OBJECTIVES The investment will support MS Pharma's expansion in the region, including the acquisition of a brownfield pharmaceutical plant in Turkey, purchase of files for the development and commercialisation of new generic pharmaceutical products, and working capital to support itsoperations in Jordan. The investment will enable MS Pharma to increase its capacity, diversify its revenues and accelerate the entry into new markets.
Investment Description
  • European Bank for Reconstruction and Development (EBRD)
Contact Information
Yazan Abu Abboudyazan. abu-abboud@mspharma.com +962 6 5827999 www.mspharma.com P.O Box 142904 Amman 11844 Jordan ACCOUNTABILITY MECHANISM OF EBRD The Project Complaint Mechanism (PCM) is the independent complaint mechanism and fact-finding body for people who have been or are likely to be adversely affected by an European Bank for Reconstruction and Development (EBRD)-financed project. If you submit a complaint to the PCM, it may assess compliance with EBRD's own policies and procedures to prevent harm to the environment or communities or it may assist you in resolving the problem that led to the complaint through a dialogue with those implementing the project. Additionally, the PCM has the authority to recommend a project be suspended in the event that harm is imminent. You can contact the PCM at pcm@ebrd.com or you can submit a complaint online using an online form, http://www.ebrd.com/eform/pcm/complaint_form?language=en. You can learn more about the PCM and how to file a complaint at http://www.ebrd.com/work-with-us/project-finance/project-complaint-mechanism.html.